Telix Pharmaceuticals ($TLX): FDA Grants BiPASS Fast Track, ITM Merger Goes To A November Vote

01 What Bulls See

Revenue that is already there. US$803.8 million in FY 2025 and roughly US$477 million in the first half of 2026 is not a projection. Very few companies in the radiopharmaceutical sector have a commercial base of this size.

The FY2025 group gross margin was approximately 53%: US$426.4 million gross profit divided by US$803.8 million revenue. A separate 64% figure in the release refers to Precision Medicine. The group financial table is the relevant basis for consolidated comparisons.

An approved diagnostic indication. Pixclara’s U.S. glioma imaging approval removes the pending regulatory event; commercial uptake remains to be demonstrated.

Separate jurisdictions. U.S. approval does not establish the outcome of the European application.

Geographic opportunity in the core product. The China Phase 3 Illuccix study reported 94.8% positive predictive value and a treatment-plan change in 67.2% of patients. The August interim update says the Chinese NDA was accepted for review; approval, reimbursement and subsequent commercial uptake remain separate requirements.

Vertical integration that competitors have to build. Manufacturing Solutions generated US$170.1 million of third-party revenue in FY 2025, which is infrastructure other radiopharma companies are paying to use.

If completed and integrated successfully, ITM would broaden isotope supply and add a late-stage therapeutic asset. This upside is conditional on closing, regulatory progress and execution.

02 What Bears See

The CRL history remains relevant, but Pixclara now has FDA approval. Zircaix remains a separate dossier; the approval does not clear every manufacturing or regulatory risk across Telix.

Different regulatory problems require different evidence. Zircaix remediation concerns chemistry, manufacturing and controls, including comparability between clinical and commercial production. The Pixclara resubmission separately involved additional clinical data and a revised statistical analysis plan before its subsequent approval. Neither history supports treating every CRL as a manufacturing-only problem.

An SEC subpoena and a securities class action. Both concern the therapeutics disclosures, which are also the disclosures that justify the increased research budget.

Recurring profitability needs examination. FY2025 adjusted EBITDA fell from US$66.9 million to US$39.5 million despite revenue growth. H1 2026 adjusted EBITDA recovered to US$52 million but includes the US$40 million Regeneron payment. Increasing R&D and manufacturing costs make the sustainability of that improvement more informative than the headline growth rate.

The June 30, 2026 cash balance of US$252 million is within the US$230–270 million annual R&D guidance range. The range does not imply that spending must exceed cash. It is an expense budget, not a cash-runway calculation; operating cash flows, financing and other expenditures matter.

Telix issued US$600 million of new convertible bonds due 2031 in April 2026 to refinance its convertible structure, as disclosed in the half-year results. Future conversion or repayment affects financing and dilution.

Share consideration, assumed ITM debt and contingent milestone payments add financing and integration exposure; the announced transaction remains conditional.

03 Scenario Framework

The scenarios combine execution of the existing imaging business with the proposed ITM transaction. They describe conditional business paths, not forecasts.

The intermediate path is continued growth of the existing imaging franchise while the ITM approval and closing process proceeds. Pixclara approval is already a completed milestone; ITM remains a proposed transaction and its economics are not included in reported standalone results.

Evidence that would change the assessment

The assessment depends on continued commercial growth, funding for development and the proposed ITM transaction. These observations could strengthen or weaken it; they are not predictions.

• ITM closing conditions. A failed vote, regulatory objection or termination would require removing the announced combination from the base scenario. Completion would instead make integration, debt and the actual shares issued measurable.
• Revenue and cash conversion. Revenue below guidance or weaker collections would challenge the growth case. Sustained operating cash generation without another large partner payment would support it.
• Zircaix documentation. An accepted resubmission would establish a new review process, not approval. Further deficiencies or withdrawal would weaken the pipeline case.
• BiPASS results and review. The completed enrollment and Fast Track designation do not establish diagnostic performance or approval in the pre-biopsy setting. Study data, an accepted application and any eventual label answer distinct questions.
• Legal developments. A ruling, settlement or enforcement action could change risk and potential costs. Whether any amount becomes a recognized liability depends on its terms and the applicable accounting assessment; allegations alone are not a quantified liability.

06 What The Company Actually Is

The company reports across three business areas, and reading them separately is the only way to make sense of the revenue line.

That table contains the whole investment argument in miniature. Precision Medicine is growing at 30% and carries the company. Manufacturing Solutions is shrinking modestly year on year. Therapeutics generates nothing and absorbs the majority of a research budget guided at up to US$270 million.

07 Illuccix And Gozellix: The Commercial Base

Grand Pharmaceutical Group is Telix’s strategic commercial partner for Greater China, identified in the December 2025 Illuccix update. In its BiPASS Fast Track announcement, Telix estimated more than three million prostate biopsies globally each year, with up to 75% negative. This company-cited clinical context is not the addressable paid-scan volume. Telix SEC filing on the Pixclara approval. Telix precision medicine portfolio update. Telix SEC filing, September 30, 2026.

Illuccix is a kit for the preparation of gallium-68 gozetotide injection, used for PSMA-PET imaging in prostate cancer. It is the product that made Telix a commercial company, and the company states it is commercially available in 22 countries including the United States. Gozellix has also received FDA approval.

The most concrete recent datapoint on this franchise is geographic rather than American. In the December 2025 portfolio update Telix reported that the Phase 3 study of Illuccix in China met its primary endpoint, with an overall patient-level positive predictive value of 94.8% (95% CI: 85.9%, 98.2%) across 140 patients, and that 67.2% of patients had their treatment plan changed as a result of the PSMA-PET imaging.

The treatment-plan change is evidence of clinical decision impact in that study. It does not establish repeat orders, improved survival or future revenue. Commercial performance in China still depends on the regulatory decision, reimbursement, distribution and physician adoption; these should be measured separately from positive predictive value.

September 2, 2026: BiPASS completes enrollment. Telix announced that the Phase 3 BiPASS study of Illuccix and Gozellix in the pre-biopsy setting has completed enrollment of 350 patients in the United States and Australia, and that it has aligned with the FDA on a New Drug Application pathway which, if approved, would support reimbursement as a new product. BiPASS is described by the company as the first registrational study of gallium-68 PSMA-PET imaging before biopsy, building on the PRIMARY and PRIMARY2 studies. What the release contains is an enrollment milestone and a regulatory route; it contains no results, no readout date and no filing date, and the reimbursement it points to depends on an application that has still to be submitted and reviewed.

08 Pixclara: FDA Approval Announced September 14

For Pixclara, the September 14, 2026 approval announcement cites approximately 24,000 new U.S. glioma diagnoses annually. That incidence estimate describes potential clinical need, not scans sold, reimbursement or revenue. Telix SEC filing on the Pixclara approval. Telix precision medicine portfolio update. Telix SEC filing, September 30, 2026.

Source: Telix announcement, September 14, 2026

The regulatory history is not clean, and reading it in order matters.

The application carries Orphan Drug and Fast Track designations, and Telix has pointed out that 18F-FET is already broadly recommended in international clinical practice guidelines, including NCCN guidelines. That is a genuine argument: the agent is used in Europe, and the unmet need is documented. It is also an argument the FDA has already heard once, since this is a resubmission after a Complete Response Letter.

A European marketing authorisation application has also been submitted, which spreads the regulatory risk across two agencies rather than concentrating it in one.

Source: Telix announcement, September 14, 2026

The September 14 and 15 investor conferences are historical appearances, not future catalysts. Their dates are distinct from the September 11 target FDA action date and the September 14 announcement of approval.

Official calendar

The NDA was resubmitted on March 13, 2026 after a Complete Response Letter and accepted for standard review on April 10, 2026, for imaging of recurrent or progressive glioma in adult and paediatric patients. Orphan Drug and Fast Track designations apply.

09 Zircaix: The CRL That Is Not Yet Closed

The pivotal ZIRCON study enrolled 300 patients, with 284 evaluable. The company’s February 2025 summary reports 86% sensitivity, 87% specificity and 93% positive predictive value for clear-cell renal-cell carcinoma across three independent readers. These are diagnostic-performance measures in the study population, not treatment-response rates. Telix release: FDA accepts BLA for TLX250-CDx (Zircaix) with priority review.

TLX250-CDx, brand name Zircaix, is a zirconium-89 labelled girentuximab antibody for imaging clear cell renal cell carcinoma. The BLA was accepted with priority review in February 2025, which at the time was read as a near-term approval.

On August 28, 2025 the FDA issued a Complete Response Letter citing manufacturing deficiencies. The stock fell more than 21% on the disclosure. The FDA also documented deficiency notices at two third-party manufacturing partners requiring remediation before any resubmission.

In the December 22, 2025 portfolio update Telix reported a positive Type A meeting with the FDA to align on remediation of the CMC deficiencies, with a further meeting scheduled to discuss comparability data between the product used in the ZIRCON study and the commercial manufacturing process. In the April 2026 quarterly update the company described the BLA as being prepared for resubmission in the first half of 2026 and said alignment had been reached with the FDA on the critical issues.

The August 20, 2026 update describes Zircaix resubmission preparation and an extended resubmission deadline following a corrected CRL. Pixclara approval does not resolve this separate dossier. A later filing is needed to establish a new accepted submission or action date.

The corrected CRL was dated April 10, 2026. The August interim report describes an extended resubmission deadline and continued work on outstanding items, without announcing an accepted resubmission. A new filing is needed to establish the next formal review timetable.

10 The therapeutics pipeline

The August 20 interim report separates therapeutic programs from the BiPASS diagnostic study. All therapeutic candidates below remain investigational; trial progression is not marketing authorization.

Primary source

These milestones describe different evidentiary stages. Safety and dosimetry support the ability to continue development, while efficacy, manufacturing, trial execution and regulator review remain distinct risks. A completed enrollment is not a completed analysis, and an imaging-product approval does not authorize a therapeutic version with a different isotope and intended use.

11 Manufacturing Solutions And The Vertical Integration Bet

The September 21 announcement describes ITM’s 2025 revenue of $273 million, a 40% compound annual growth rate over 2021–2025, and distribution across more than 65 countries. Its isotope capabilities include lutetium-177, actinium-225 and terbium-161. ITM-11 completed COMPETE and fully enrolled COMPOSE, whose interim analysis was expected in H1 2027. Management estimated combined unaudited pro forma 2026 revenue and income above $1.3 billion; this is a forecast for the combined businesses, not Telix’s standalone reported revenue or proof the transaction has closed. Telix SEC filing, September 21, 2026.

Telix Manufacturing Solutions generated US$45 million in the second quarter of 2026, down 6% year on year and up 2% sequentially. In FY 2025 the segment produced US$238.4 million, of which US$170.1 million came from third parties.

The strategic logic is straightforward. Radiopharmaceuticals decay; they cannot be stockpiled and shipped the way a tablet can. Owning radiopharmacy and distribution capacity is what makes a same-day imaging agent commercially viable at scale, and it also creates a third-party revenue stream from other companies that need the same infrastructure.

Infrastructure ownership also creates capital, staffing, quality and regulatory obligations. H1 2026 Manufacturing Solutions reported an adjusted EBITDA loss of US$23 million; the company attributes this to investment in supply chain and logistics for anticipated therapeutic demand. Future utilization and economics must justify that spending. Problems at third-party partners do not by themselves establish a defect at every owned facility.

12 Revenue Trajectory And Guidance

The guidance was revised upward at the July 21, 2026 update. Group revenue guidance for FY 2026 is US$950 to US$970 million, and the company describes revenue and other income together as expected to exceed US$1 billion once a US$40 million non-refundable payment from Regeneron is included.

Two observations follow. First, the distinction between revenue and other income is not cosmetic: a one-off non-refundable partner payment is not a product sale, and the company itself presents them separately. Second, half-year revenue of roughly US$477 million against full-year guidance of US$950-970 million implies the second half needs to look very much like the first, with no acceleration required and none assumed.

13 Financials

Telix reported its half-year results on August 20, 2026, and lodged them with the SEC on a Form 6-K the same day. That report replaces the FY 2025 accounts as the most recent complete income statement, and it answers three questions that were open until then: the first-half revenue in the interim financial report, the June 30 cash balance, and what the Regeneron payment did to profitability.

One-off income affects the comparison. H1 profit after tax of US$38 million includes US$40 million of Regeneron income. Subtracting that gross receipt from after-tax profit is not a properly tax-adjusted earnings measure, but it shows why the headline is not a measure of recurring product profitability. Revenue and gross profit measure a different part of performance; the latter was approximately US$260 million, at a 55% group margin and 65% Precision Medicine margin.

Where the spending went. Research and development rose from US$82 million to US$124 million, up 52%, of which US$68 million went to the therapeutics pipeline. Selling and marketing rose 19% and manufacturing and distribution 52%, the latter reflecting the build-out of the manufacturing segment. General and administration was essentially flat. Spending is growing faster than revenue by design, and the company has reaffirmed full-year R&D guidance of US$230 to 270 million.

Segments. Precision Medicine revenue grew 27% year on year with segment adjusted EBITDA of US$132 million, up 26%. Manufacturing Solutions reported US$146 million of total segment revenue, of which US$89 million from third-party sales and service fees and US$58 million internal, with an operating loss of US$33 million and an adjusted EBITDA loss of US$23 million against a US$13 million loss a year earlier. The manufacturing arm is being funded, not harvested.

The FY 2025 comparison below is kept because it is the last full-year picture and it frames the trajectory.

The FY2025 consolidated financial table reports US$426.4 million gross profit on US$803.8 million revenue, a calculated margin of approximately 53%, versus approximately 65% in 2024. Adjusted EBITDA fell to US$39.5 million from US$66.9 million. Product-development investment of US$157.1 million and the IFRS research-and-development expense of US$171.2 million are different measures.

FY2026 R&D guidance of US$230–270 million and FY2025 product-development investment of US$157.1 million are company operating measures; FY2025 IFRS R&D expense was US$171.2 million. Differences between measures matter when comparing annual spending.

14 Balance Sheet And Capital Structure

The H1 results report US$252 million cash at June 30 and US$23 million net operating cash flow. The US$40 million Regeneron receipt is included in that operating cash flow, not an additional amount to add to it. April refinancing issued US$600 million convertible bonds due 2031.

The H1 2026 accounts report positive operating cash flow of US$23 million, US$252 million cash and US$600 million of newly issued convertible bonds. Annual R&D guidance is an expense budget, not a standalone cash runway calculation. Cash conversion, refinancing, investment and deal obligations should be assessed together.

A new at-the-market facility, announced the same day

In the same August 20 announcement, Telix disclosed that it had entered into an equity distribution agreement with Morgan Stanley & Co. LLC and William Blair & Company, L.L.C. to establish an at-the-market facility. Under it the company may issue new fully paid ordinary shares at prevailing market prices, in the form of American Depositary Shares on Nasdaq.

The August 20 announcement establishes an ATM facility and describes conditions for offers or sales. It does not establish whether later filings or sales have occurred.

Potential dilution remains relevant. The ATM gives management financing flexibility. Establishing the facility does not prove sales, and profitability does not prove that funding will never be needed. Actual use can only be estimated from any prospectus supplement, issued-share disclosure and subsequent financing report.

Trace the cash increase. The half-year cash-flow statement reports US$23.036 million from operations, US$33.717 million used in investing and US$118.427 million from financing. Together these produce a US$107.746 million cash increase before US$2.298 million of currency effects, taking opening cash of US$141.866 million to US$251.910 million. The refinancing contributed US$587.453 million of proceeds while repayments consumed US$466.453 million; the gross bond issue was not all new spending capacity.

The US$40 million Regeneron receipt is already inside operating cash flow. A mechanical subtraction leaves negative US$16.964 million, an analytical comparison rather than a company-reported adjusted cash metric. It explains why positive reported operating cash cannot alone demonstrate that recurring activity fully funds the development plan. Capital expenditure, acquisition payments and financing movements are excluded from that calculation. Primary source

Milestone timing is specific. The ITM agreement allocates up to US$250 million to three possible FDA approvals: US$100 million for G1–G2 GEP-NETs by December 31, 2027, US$100 million for G2–G3 GEP-NETs by December 31, 2030, and US$50 million for lung NETs by December 31, 2031. A separate amount of up to US$450 million depends on FY2030 global ITM-11 sales above US$150 million. These are contractual payment conditions, not promised approval dates or sales guidance. Telix may elect cash or shares under the agreed terms. Primary transaction filing

15 Listing Structure, ADS And Reporting Status

Telix is primarily listed on the Australian Securities Exchange under TLX. American Depositary Shares began trading on Nasdaq under the same ticker on November 14, 2024, with JPMorgan Chase Bank, N.A. as depositary. Each ADS represents one fully paid ordinary share, which is unusual and convenient: the Nasdaq price and the ASX price are directly comparable once currency is accounted for, with no ratio adjustment.

The company registered on Nasdaq via a Form 20-F registration statement and files with the SEC under CIK 0002007191. The practical consequence for a reader used to American small caps is that there is no 10-Q. Telix reports on the Australian cycle: half-year and full-year results, with quarterly business updates in between that carry revenue and pipeline but not a full balance sheet.

The June 30 cash balance was approximately three months old as of October 4. Interim balance-sheet reporting and quarterly commercial updates have different frequencies.

The ASX ordinary-share and Nasdaq ADS lines have different trading venues. Liquidity varies by trading venue and changes over time.

16 Litigation and the SEC inquiry

The interim report is the primary source for the status disclosed on August 20, 2026. Telix describes an SEC subpoena concerning disclosures about prostate cancer therapeutic candidates as a fact-finding request. It says it is cooperating, no charges have been asserted against the group or its personnel, and no conclusions have been reached. The company could not predict the inquiry’s duration, scope or outcome.

The same report states that a putative securities class action was filed in the Southern District of Indiana on November 10, 2025 and served on January 20, 2026. Telix had filed a motion to dismiss. At the report date, no class had been certified and no dispositive motion had been decided. These are procedural facts as of that disclosure, not a claim that the docket cannot have changed subsequently.

A plaintiffs’ law-firm release describes allegations about therapeutic-development disclosures and third-party manufacturing. Such allegations are not judicial findings. An FDA response letter addresses a regulatory application and does not itself decide securities-law liability. Litigation costs are expensed as incurred according to the report; no damages amount or settlement outcome is established by these sources. Interim report, note 10